New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

Today's Free Fly Stories
All of the free stories from today.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | all day >>
08:13 EDTFCXFreeport McMoRan says encouraged by talks with the Indonesian government
Subscribe for More Information
08:12 EDTDOXAmdocs management to meet with Oppenheimer
Subscribe for More Information
08:12 EDTRHIRobert Half price target raised to $57 from $49 at BMO Capital
BMO Capital increased its price target on Robert Half after the company reported higher than expected Q2 EPS and provided higher than expected Q3 EPS guidance. The firm notes that annual revenue growth accelerated in every segment except Robert Half Technology, while operating margins increased at the company's three major segments. The firm keeps an Outperform rating on the shares.
08:11 EDTDOXAmdocs management to meet with Jefferies
Subscribe for More Information
08:11 EDTCVMCEL-SCI cleared to begin patient enrollment
Subscribe for More Information
08:11 EDTYGE, GEYingli Green Energy to supply PV modules to large project in Japan
Yingli Green Energy's (YGE) wholly-owned subsidiary, Yingli Green Energy Japan, has signed an agreement to supply 32 MWs of multicrystalline PV modules to a large-scale project located in Okayama, Japan. The company will deliver approximately 108K YGE 72 Cell Series modules for the project from January 2015 to December 2015. The project is financed by GE (GE) Energy Financial Services.
08:11 EDTKINGKing Digital downgraded at BofA/Merrill
Subscribe for More Information
10:45 EDTTEVA, MNK, JAZZ, ACT, PRGO, ENDP, MYL, VRX, HSP, SLXP, TEVA, MNK, JAZZ, ACT, PRGO, ENDP, MYL, VRX, HSP, SLXPDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
08:10 EDTBMRNBioMarin, Sarah Cannon Research UK collaborate on EMBRACA clinical study
BioMarin Pharmaceutical and Sarah Cannon Research UK announced a collaboration to enroll patients in an ongoing Phase 3 clinical trial of its PARP inhibitor, BMN 673, for the treatment of hereditary breast cancer with a BRCA mutation. This ongoing Phase 3 trial has recently been named EMBRACA. Sarah Cannon Research UK enrolled the first patient outside of the United States, expanding the trial internationally.
08:09 EDTFNRGForceField Energy signs LOI to acquire ESCO Energy Services
Subscribe for More Information
08:08 EDTALKAlaska Air names David L. Campbell COO of subsidiary Horizon Air
Subscribe for More Information
08:08 EDTAAPL, AAPLApple price target raised to $120 from $115 at CLSA
08:08 EDTFCFFirst Commonwealth reports Q2 EPS 13c, consensus 13c
Subscribe for More Information
08:08 EDTFCXFreeport McMoRan sees FY14 operating cash flows $6.8B
Subscribe for More Information
08:07 EDTLIQTLiqTech 6.96M share Secondary priced at $1.50
The deal size was increased to 6.96M shares from 5M shares. Craig-Hallum acted as sole book running manager for the offering.
08:07 EDTCORCoreSite Realty raises FY14 FFO outlook to $2.07-$2.15 from $2.00-$2.10
Subscribe for More Information
08:07 EDTOIIMO2Micro reports Q2 EPS (12c), consensus (8c)
Subscribe for More Information
08:06 EDTVMWVMware upgraded at CLSA
As previously reported, CLSA upgraded VMware to Buy from Outperform. The firm upgraded shares after the Q2 report citing expectations for solid growth, new product introductions, and the potential spin-off from EMC (EMC) following recent actions by Elliott Management. Price target is $115.
08:06 EDTLGFLionsgate partners with Finnish game developer Next Games
Subscribe for More Information
08:06 EDTFCXFreeport McMoRan sees Q3 copper sales 1.1B lb, gold sales 445K oz
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | all day >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use